Characterizing microglial gene expression in a model of secondary progressive multiple sclerosis

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Dokumenter

  • Fulltext

    Forlagets udgivne version, 3,84 MB, PDF-dokument

  • Ilia D. Vainchtein
  • Astrid M. Alsema
  • Marissa L. Dubbelaar
  • Corien Grit
  • Jonathan Vinet
  • Hilmar R. J. van Weering
  • Sarah Al-Izki
  • Giuseppe Biagini
  • Nieske Brouwer
  • Sandra Amor
  • David Baker
  • Bart J. L. Eggen
  • Boddeke, Erik
  • Susanne M. Kooistra

Multiple sclerosis (MS) is the most common inflammatory, demyelinating and neurodegenerative disease of the central nervous system in young adults. Chronic-relapsing experimental autoimmune encephalomyelitis (crEAE) in Biozzi ABH mice is an experimental model of MS. This crEAE model is characterized by an acute phase with severe neurological disability, followed by remission of disease, relapse of neurological disease and remission that eventually results in a chronic progressive phase that mimics the secondary progressive phase (SPEAE) of MS. In both MS and SPEAE, the role of microglia is poorly defined. We used a crEAE model to characterize microglia in the different phases of crEAE phases using morphometric and RNA sequencing analyses. At the initial, acute inflammation phase, microglia acquired a pro-inflammatory phenotype. At the remission phase, expression of standard immune activation genes was decreased while expression of genes associated with lipid metabolism and tissue remodeling were increased. Chronic phase microglia partially regain inflammatory gene sets and increase expression of genes associated with proliferation. Together, the data presented here indicate that microglia obtain different features at different stages of crEAE and a particularly mixed phenotype in the chronic stage. Understanding the properties of microglia that are present at the chronic phase of EAE will help to understand the role of microglia in secondary progressive MS, to better aid the development of therapies for this phase of the disease.

OriginalsprogEngelsk
TidsskriftGlia
Vol/bind71
Udgave nummer3
Sider (fra-til)588-601
Antal sider14
ISSN0894-1491
DOI
StatusUdgivet - 2023

ID: 327944309